MAIA Biotechnology (NYSEAMERICAN:MAIA) Stock Price Up 3.3% – Still a Buy?

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) traded up 3.3% during trading on Friday . The stock traded as high as $1.59 and last traded at $1.58. 102,294 shares were traded during mid-day trading, a decline of 73% from the average session volume of 384,973 shares. The stock had previously closed at $1.53.

MAIA Biotechnology Stock Performance

The company’s fifty day moving average price is $1.69 and its 200 day moving average price is $1.76. The firm has a market capitalization of $52.12 million, a price-to-earnings ratio of -2.77 and a beta of 0.01.

Insider Transactions at MAIA Biotechnology

In other news, Director Stan Smith bought 33,333 shares of MAIA Biotechnology stock in a transaction on Tuesday, June 3rd. The stock was purchased at an average cost of $1.50 per share, with a total value of $49,999.50. Following the purchase, the director directly owned 1,305,059 shares of the company’s stock, valued at approximately $1,957,588.50. This trade represents a 2.62% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 32.32% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Geode Capital Management LLC boosted its stake in MAIA Biotechnology by 3.6% during the 2nd quarter. Geode Capital Management LLC now owns 222,183 shares of the company’s stock valued at $400,000 after purchasing an additional 7,746 shares during the period. Centerpoint Advisory Group acquired a new position in MAIA Biotechnology during the 2nd quarter valued at about $28,000. Marshall Wace LLP acquired a new position in MAIA Biotechnology during the 2nd quarter valued at about $29,000. Jane Street Group LLC bought a new stake in shares of MAIA Biotechnology during the 2nd quarter worth about $52,000. Finally, Centric Wealth Management raised its position in shares of MAIA Biotechnology by 740.2% during the 2nd quarter. Centric Wealth Management now owns 573,398 shares of the company’s stock worth $1,032,000 after buying an additional 505,150 shares in the last quarter. 5.65% of the stock is owned by institutional investors and hedge funds.

About MAIA Biotechnology

MAIA Biotechnology, Inc, a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer.